Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $65.00 Price Target at Oppenheimer

Tarsus Pharmaceuticals (NASDAQ:TARS - Free Report) had its price target lifted by Oppenheimer from $63.00 to $65.00 in a research note published on Thursday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Separately, William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $52.00.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS traded up $0.56 on Thursday, reaching $47.07. 790,722 shares of the company traded hands, compared to its average volume of 724,645. Tarsus Pharmaceuticals has a fifty-two week low of $15.60 and a fifty-two week high of $52.99. The company's 50 day moving average is $37.17 and its 200-day moving average is $32.33. The stock has a market capitalization of $1.79 billion, a PE ratio of -11.09 and a beta of 1.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC lifted its position in shares of Tarsus Pharmaceuticals by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company's stock worth $6,924,000 after buying an additional 29,465 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Tarsus Pharmaceuticals by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company's stock worth $66,398,000 after purchasing an additional 231,131 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Tarsus Pharmaceuticals during the 1st quarter worth about $12,640,000. Russell Investments Group Ltd. lifted its position in shares of Tarsus Pharmaceuticals by 38,907.8% during the 1st quarter. Russell Investments Group Ltd. now owns 30,036 shares of the company's stock worth $1,092,000 after purchasing an additional 29,959 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $28,904,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.